Breaking Finance News

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has been downgraded to Sell in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded Agios Pharmaceuticals Inc (NASDAQ:AGIO) to Sell in a statement released on 10/05/2016.

Boasting a price of $54.30, Agios Pharmaceuticals Inc (NASDAQ:AGIO) traded 2.14% higher on the day. The last stock price is up 18.19% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. AGIO has recorded a 50-day moving average of $44.94 and a 200-day moving average of $46.06. 304,611 shares of AGIO traded, down from an avg. volume of 662,865

Recent Performance Chart

Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Agios Pharmaceuticals Inc has one year low of $33.50 and a one year high of $81.77 and has a market cap of $0.

In addition to Zacks Investment Research reporting its target price, a total of 7 analysts have released a research note on Agios Pharmaceuticals Inc. The 12-month price target is $55.57 with zero analysts rating the company a strong buy, three analysts rating the company a buy, five brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.